Danaher Reports Second Quarter 2022 Results

KeyBanc Remains Positive on Life Sciences as 'Strong' Earning Season Begins with Danaher (DHR) Report

KeyBanc analyst Paul Knight comments "Bioprocess market leaders Sartorius (SRT3) and Danaher (DHR) published 2Q22 results this morning with strong revenue and EPS beats, providing a positive backdrop for the industry at large. Results clearly indicate bioprocess companies are witnessing high-levels of demand, making up for the headwinds posed... More

UBS on Danaher (DHR): 'we believe the CPHD platform will continue to see traction as COVID-19 becomes endemic'

UBS analyst Elizabeth Garcia reiterated a Buy rating and $297.00 price target on Danaher (NYSE: DHR).

The analyst comments "DHR kicked off 2Q22 life sciences tools earnings and reported a 2Q beat driven by the base business (+8% vs. +MSD% guidance) and COVID (+1.5% vs. -LSD... More

Cowen Reiterates Outperform Rating on Danaher (DHR), 'We expect the stock to react favorably'

Cowen analyst Dan Brennan reiterated an Outperform rating and $343.00 price target on Danaher (NYSE: DHR).

The analyst comments "Total organic growth of 9.5% well ahead of 'LSD%' guide and our 1.8%, with organic growth ex COVID testing ('base growth') of 8.0% ahead of our 4.3%.... More

Stifel Reiterates Hold Rating on Danaher (DHR), 'we are impressed with the company's ability to perform'

Stifel analyst Daniel Arias reiterated a Hold rating and {REMOVEPT} price target on Danaher (NYSE: DHR).

The analyst comments "Danaher reported 2Q22 revenues of $7.75B (+7.5% y/y), which was above Stifel ($7.12B) and consensus ($7.31B). Core revenue growth of 9.5% was ahead of expectations on... More

Danaher (DHR) Tops Q2 EPS by 40c

Danaher (NYSE: DHR) reported Q2 EPS of $2.76, $0.40 better than the analyst estimate of $2.36. Revenue for the quarter came in at $7.8 billion versus the consensus estimate of $7.32 billion.

For earnings history and earnings-related data on Danaher (DHR) click here.